EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Andrea Duminuco iD, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile iD, Vanessa Innao iD und 10 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70638 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Andrea Duminuco und 21 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia', University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Benzamides, Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Pyrazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy. This retrospective multicentre study evaluated acalabrutinib monotherapy across 10 Italian haematology centres (2021–2025), including 155 adults with CLL/small lymphocytic lymphoma (SLL) (median age 74 years, 44.5% ≥75 years, 35.5% relapsed/refractory, 59.4% cardiovascular comorbidities, 24.5% del17p/TP53). Primary end‐point was time‐to‐discontinuation (TTD ≥28 days interruption/progression/death); secondary included response rates (based on International Workshop on Chronic Lymphocytic Leukemia criteria), haematological recovery, overall survival (OS) and safety. Median TTD was not reached (16 months follow‐up), overall response rate 84.5% (32.9% clinical complete remission, reinforced by bone marrow evaluation in four cases), OS median not reached (78.7% alive), reporting rapid haematological recovery occurred (at 6 months haemoglobin 11.1–12.6 g/dL, platelets 146–160 × 10 9 /L, lymphocytes 57.5–12.3 × 10 9 /L; p < 0.001), uniform across subgroups (no TTD differences by age/line/cardiovascular comorbidities/biology; p > 0.05), without reduction of neutrophils ( p = 0.48). Discontinuation was 20% (primarily due to adverse events), with low cardiovascular toxicity (one grade 3 atrial fibrillation). This study confirms acalabrutinib's durable effectiveness and tolerability in unselected real‐world CLL, above in patients with prior cardiovascular comorbidities, confirming clinical trial results also in frail elderly/high‐risk patients, supporting its broad adoption in routine care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsPyrazinesAgedAged, 80 and overFemaleHumansMaleMiddle AgedItalyRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

acalabrutinibcardiovascular comorbiditieschronic lymphocytic leukaemiareal‐world experiencetime‐to‐discontinuation

Substanzen

acalabrutinibBenzamidesProtein Kinase InhibitorsPyrazines

Autor:innen und Institutionen

  • Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia', University of Catania, Catania, Italy.
  • Hematology Unit With BMT, AOU Policlinico 'G.Rodolico-San Marco', Catania, Italy.
  • Hematology Section, A.O.U. Policlinico 'G. Martino', University of Messina, Messina, Italy.
  • Hematology Unit, Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.
  • Faculty of Medicine and Surgery, 'Kore' University of Enna, Enna, Italy.
  • Hematology Unit, Ospedale 'San Vincenzo', Taormina, Italy.

ORCID-Profile: Andrea Duminuco, Massimo Gentile, Vanessa Innao

Zitieren

APA

Duminuco, A., Leotta, D., Allegra, A., Caracciolo, D., Caruso, L., Chiarenza, A., Del Fabro, V., Di Martina, V., Figuera, A., Fiumara, P. F., Gentile, M., Innao, V., Mancuso, S., Martino, E. A., Mosca, A., Motta, G., Pedalino, F., Rossi, M., Stagno, F., …, & Palumbo, G. A. (2026). Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.70638

Vancouver

Duminuco A, Leotta D, Allegra A, Caracciolo D, Caruso L, Chiarenza A, et al. Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience. British Journal of Haematology. 2026. doi:10.1111/bjh.70638

BibTeX
@article{Duminuco2026,
  author = {Duminuco, Andrea and Leotta, Dario and Allegra, Alessandro and Caracciolo, Daniele and Caruso, Laura and Chiarenza, Annalisa and Del Fabro, Vittorio and Di Martina, Valentina and Figuera, Amalia and Fiumara, Paolo Fabio and Gentile, Massimo and Innao, Vanessa and Mancuso, Salvatrice and Martino, Enrica Antonia and Mosca, Antonio and Motta, Giovanna and Pedalino, Francesca and Rossi, Marco and Stagno, Fabio and Tona, Giorgio and Di Raimondo, Francesco and Palumbo, Giuseppe Alberto},
  title = {Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70638}
}
Kostenlos starten →